Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xinkening Capsules is a Traditional Chinese Medicine (TCM) developed and manufactured by Shaanxi Dongtai Pharmaceutical. It is primarily indicated for cardiovascular conditions, including coronary heart disease and angina pectoris. The formulation typically includes a complex mixture of herbal and animal-derived ingredients such as Hawthorn (Crataegus pinnatifida), Salvia miltiorrhiza (Danshen), Panax notoginseng (Sanqi), Borneol, Toad Venom, and Artificial Musk. Its therapeutic actions are characterized in TCM terms as promoting blood circulation, dissipating blood stasis, and inducing resuscitation to relieve pain. Clinically, it is used to alleviate symptoms like chest tightness, palpitations, and dizziness associated with myocardial ischemia. The product is approved by the National Medical Products Administration (NMPA) in China (Approval No. Z20025087).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on xinkening.